Divalproex Sodium

Introduction Overview

Generic Name

divalproex sodium

Brand Name

Depakote, Depakote ER, Depakote Sprinkles

Dosage Form

Tablet, film coated, extended release

Drug Class

Fatty acid derivative anticonvulsants

Pharmacokinetics

Absorption:
Divalproex sodium extended-release tablets exhibit high oral bioavailability (~90%) relative to intravenous administration. The absorption is gradual, with a median time to peak plasma concentration (Cmax) ranging from 4 to 17 hours post-dose due to the extended-release formulation. When administered once daily, steady-state plasma concentrations demonstrate lower peak-to-trough fluctuation compared to delayed-release formulations administered multiple times daily, thereby providing more stable valproate plasma levels. The bioavailability of extended-release tablets is approximately 89% relative to equal total daily doses of delayed-release tablets. Food intake does not significantly affect the bioavailability, but dosing with food may help reduce GI irritation.

Distribution:
Valproate exhibits concentration-dependent plasma protein binding predominantly to albumin, with free drug fraction increasing from about 10% at plasma concentrations of 40 mcg/mL to 18.5% at 130 mcg/mL. Protein binding is reduced in elderly patients, those with hepatic or renal impairment, and in hyperlipidemia, increasing free drug availability. Valproate displaces other protein-bound drugs such as phenytoin, carbamazepine, warfarin, and tolbutamide, resulting in clinically significant drug interactions. Cerebrospinal fluid concentrations approximate the unbound plasma concentrations (~10% of total), indicating valproate readily crosses the blood-brain barrier to exert CNS effects.

Metabolism:
Divalproex sodium is primarily metabolized hepatically via glucuronidation (30-50% of clearance) and mitochondrial beta-oxidation accounting for over 40%. Minor oxidative pathways contribute to less than 15-20% of metabolism. Metabolism follows nonlinear kinetics due to saturable plasma protein binding; total plasma concentrations do not increase proportionally with dose, but unbound drug kinetics are linear. Enzyme-inducing antiepileptics (e.g., carbamazepine, phenytoin, phenobarbital) accelerate valproate clearance.

Elimination:
The mean total valproate plasma clearance is approximately 0.56 L/hr/1.73 m2, with a volume of distribution around 11 L/1.73 m2. Free valproate clearance is higher (~4.6 L/hr/1.73 m2) with larger volume of distribution (~92 L/1.73 m2). The terminal half-life ranges from 9 to 16 hours in monotherapy. Less than 3% of unchanged drug is renally excreted. Clearance is reduced in elderly and hepatically impaired patients, necessitating dose adjustments. Patients receiving enzyme-inducing drugs exhibit increased clearance and decreased half-life.

Specific Populations:
Pediatric pharmacokinetics reveal higher clearances adjusted for body weight compared to adults, with once daily dosing producing plasma profiles similar to adults in children aged 10-17. Elderly patients have reduced clearance by ~39% and an increased free fraction by ~44%, suggesting need for lower initiation doses. Hepatic disease impairs metabolism and increases free drug fraction, requiring careful monitoring. Renal impairment modestly reduces clearance but does not necessitate significant dosing changes.

Dosage Forms

Available Dosage Forms:
- Divalproex sodium extended-release tablets, 250 mg: Pink, oval, biconvex, film-coated tablets, imprinted "U 380".
- Divalproex sodium extended-release tablets, 500 mg: Yellow, oval, biconvex, film-coated tablets, imprinted "U 381".

Dosages for Adults and Adolescents:
- Mania:
- Initial dose: 25 mg/kg/day once daily, titrate rapidly to achieve therapeutic plasma valproate levels (85-125 mcg/mL).
- Maximum dose: 60 mg/kg/day.
- Complex Partial Seizures:
- Monotherapy: Start 10-15 mg/kg/day, increase weekly by 5-10 mg/kg/day to optimal response.
- Adjunctive: Begin 10-15 mg/kg/day, titrate as above.
- Therapeutic plasma levels generally 50-100 mcg/mL.
- Max dose: 60 mg/kg/day.
- Absence Seizures:
- Start at 15 mg/kg/day, increase weekly by 5-10 mg/kg/day until seizure control or limiting side effects.
- Max dose: 60 mg/kg/day.
- Migraine Prophylaxis:
- Start with 500 mg once daily for 1 week, then increase to 1,000 mg once daily.
- Dose adjustments individualized; delayed-release formulations may be used for dose flexibility.

Specific Patient Populations:
- Pediatric Patients (≥10 years): Dosing comparable to adults; younger children (<2 years) have increased risk of hepatotoxicity, use with caution.
- Elderly patients: Start with lower doses than adults; titrate slowly due to reduced clearance and increased free fraction.
- Hepatic impairment: Contraindicated.
- Conversion from delayed-release to extended-release requires dose increase of 8-20% to achieve comparable plasma exposure.

Additional Instructions:
- Extended-release tablets should be swallowed whole; do not crush or chew.
- Compliance with once-daily dosing critical for efficacy and tolerability.
- Dosing adjustments guided by clinical response and plasma valproate concentrations.
- In patients co-administered enzyme-inducing AEDs, higher doses may be required due to increased clearance.
- Dose-related adverse reactions such as thrombocytopenia more frequent at plasma concentrations above 110 mcg/mL (females) and 135 mcg/mL (males).

Mechanism Of Action

Divalproex sodium dissociates in the gastrointestinal tract to valproate ion, which is the active moiety responsible for therapeutic effects. Its primary mechanism in epilepsy is thought to be increasing gamma-aminobutyric acid (GABA) concentrations in the brain by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase, enzymes involved in GABA catabolism. This elevation in GABAergic activity enhances inhibitory neurotransmission, dampening neuronal excitability and seizure activity.

Valproate also modulates neuronal firing by blocking voltage-gated sodium channels and T-type calcium channels, stabilizing neuronal membranes, and suppressing repetitive neuronal firing. These electrophysiological modulations contribute to its anticonvulsant, mood-stabilizing, and migraine prophylactic properties. The drug’s mood-stabilizing effects in bipolar disorder are attributed to these combined neuronal mechanisms, along with inhibition of histone deacetylases affecting gene expression and neuroplasticity.

Clinically, valproate’s broad spectrum of activity reflects its diverse actions on neurotransmitter systems and ion channels. Comparative to other anticonvulsants, its ability to increase inhibitory GABAergic tone distinguishes it from drugs that act primarily by sodium channel blockade. Unlike many agents, valproate’s multitarget mechanism accounts for its utility across epilepsy types, bipolar mania, and migraine prophylaxis.

Research studies have demonstrated valproate’s efficacy correlates with plasma concentrations achieving sufficient brain GABA increases, though exact pharmacodynamic relationships vary between conditions. The drug’s nonlinear pharmacokinetics and concentration-dependent protein binding complicate dose titration. Ongoing investigations explore valproate’s epigenetic effects and mitochondrial influences, which may underlie some adverse effects and contraindications, particularly in mitochondrial disorders.

Pharmacological Actions

Anticonvulsant activity through enhancement of GABAergic inhibitory neurotransmission.
Mood stabilization via modulation of neuronal excitability and gene expression, effective in bipolar disorder manic episodes.
Inhibition of voltage-gated sodium and T-type calcium channels to suppress seizure propagation.
Prophylaxis of migraine headaches by stabilizing neuronal excitability and reducing cortical spreading depression.
Neuroprotective effects attributed to histone deacetylase inhibition and epigenetic modulation.
Reduction of neuronal hyperactivity in various seizure types including complex partial and absence seizures.
Effectiveness as monotherapy and adjunctive therapy in epilepsy.
Dose-dependent effects on platelet aggregation and hemostasis, influencing bleeding risks.
Interactions with mitochondrial function implicated in contraindications and toxicities.
Influences on metabolism of other drugs via inhibition of hepatic enzymes and protein binding displacement.
Potential induction of somnolence and CNS depression, particularly in elderly patients.
Effects on hepatic enzyme systems leading to altered metabolism of concomitant drugs.
Alteration of endocrine parameters including reproductive hormones leading to fertility effects.
Modulation of neurotransmitter systems beyond GABA, including glutamate and dopamine pathways.
Increased ammonia levels leading to risk of hyperammonemic encephalopathy under certain conditions.

Therapeutic Or Clinical Uses

Treatment of acute manic or mixed episodes associated with bipolar disorder, with or without psychotic features.
Monotherapy and adjunctive therapy of complex partial seizures in adults and children aged 10 years and older.
Treatment of simple and complex absence seizures in adults and children aged 10 years and older.
Adjunctive therapy for multiple seizure types that include absence seizures.
Prophylaxis of migraine headaches in adult patients.
Management of bipolar disorder mania, especially when rapid control of symptoms is required.
Adjunctive agent in epilepsy to reduce seizure frequency and severity.
Use in pediatric patients with epilepsy aged 10 years and older, with comparable safety to adults.
Treatment option when other anticonvulsants are inadequate or not tolerated.
Utilized to prevent migraine attacks but not for acute migraine relief.
Considered in complex seizure syndromes requiring broad-spectrum anticonvulsant therapy.
Management of mood stabilization in patients with bipolar disorder unable to tolerate lithium.
Alternative to other antiepileptic drugs in neurologic conditions requiring combination therapy.
Use in patients with refractory seizures as part of a multi-drug regimen.
Employed where rapid onset of antimanic effects is beneficial due to acute symptomatology.

Side Or Adverse Effects

Common adverse effects include nausea, vomiting, diarrhea, dyspepsia, and abdominal pain.
Central nervous system effects such as somnolence, dizziness, tremor, headache, insomnia, and asthenia.
Alopecia (hair loss) reported frequently and may be reversible upon discontinuation.
Thrombocytopenia and hematologic abnormalities including leukopenia, anemia, and bone marrow suppression.
Hepatotoxicity ranging from elevated liver enzymes to fatal hepatic failure, especially within first 6 months.
Pancreatitis, sometimes hemorrhagic and potentially fatal, requiring prompt discontinuation.
Serious dermatologic reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).
Hypothermia and hyperammonemic encephalopathy, sometimes associated with concomitant topiramate use.
Increased risk of suicidal ideation and behavior across psychiatric and epileptic indications.
Gastrointestinal disturbances such as constipation, fecal incontinence, and stomatitis.
Psychiatric adverse events including agitation, hallucinations, psychosis, and behavioral changes.
Metabolic and nutritional effects such as weight gain, peripheral edema, and hypoproteinemia.
Reproductive system effects including irregular menses, amenorrhea, infertility, and hormone alterations.
Rare cases of Fanconi's syndrome, particularly in pediatric populations.
Medication residue in stool reported in patients with altered GI transit times or diarrhea.

Precautions

Monitor liver function tests before initiation and frequently during the first six months due to risk of hepatotoxicity.
Use caution in patients with a history or suspicion of mitochondrial disorders; contraindicated in POLG mutations.
Avoid use in children under two years except with extreme caution as sole agent due to increased hepatotoxicity risk.
Require pregnancy counseling and effective contraception in women of childbearing potential due to teratogenic risks.
Monitor platelet counts and coagulation parameters due to risk of thrombocytopenia and bleeding disorders.
Evaluate ammonia levels in patients presenting with unexplained lethargy, vomiting, or mental status changes.
Avoid sudden discontinuation to prevent status epilepticus and worsening seizure control.
Cautiously use in elderly patients; start with reduced doses and monitor for somnolence and nutritional status.
Screen for urea cycle disorders prior to therapy in patients with history suggestive of these metabolic abnormalities.
Exercise increased vigilance when co-administered with topiramate due to risk of hyperammonemia and encephalopathy.
Counsel patients on recognizing symptoms of pancreatitis, hepatotoxicity, dermatologic hypersensitivity, and angioedema.
Adjust dosage in patients receiving hepatic enzyme-inducing or inhibiting medications.
Advise patients to avoid alcohol to reduce risk of CNS depression and impaired hepatic function.
Inform patients about medication residue in stool and assess drug levels if this occurs.
Regularly assess mental health status for emerging or worsening depression or suicidal thoughts.

Warnings

Boxed Warning: Life-threatening hepatotoxicity, particularly within first six months; higher risk in children under two and patients with mitochondrial disorders.
Teratogenicity: High risk of major congenital malformations including neural tube defects; associated with decreased IQ and neurodevelopmental disorders in exposed fetuses.
Pancreatitis: Potentially fatal hemorrhagic pancreatitis has been reported; discontinue drug immediately if pancreatitis suspected.
Increased risk of suicidal thoughts and behaviors in patients treated with antiepileptic drugs including divalproex.
Serious dermatologic reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis can occur; discontinue at first sign of rash.
DRESS/multiorgan hypersensitivity reactions may be fatal; prompt discontinuation required if suspected.
Angioedema: Rapid onset swelling of face, lips, or throat necessitating immediate cessation of therapy.
Hyperammonemia and encephalopathy, possibly with normal liver function tests, requiring monitoring of ammonia levels.
Hypothermia associated with valproate therapy, including cases with concurrent topiramate treatment.
Risk of bleeding and hematopoietic disorders including thrombocytopenia; monitor platelet and coagulation parameters.
Avoid use in patients with known urea cycle disorders due to risk of fatal hyperammonemia.
Potential for medication residue passage in stool, especially in patients with altered gastrointestinal function.
Application of caution in elderly patients due to increased somnolence and risk of dehydration.
Avoid abrupt discontinuation to prevent status epilepticus.
Monitor closely when initiating or withdrawing enzyme-inducing or inhibiting drugs due to pharmacokinetic interactions.

Contraindication

Patients with hepatic disease or significant hepatic dysfunction.
Known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG), including children under two years suspected of such disorders.
Known hypersensitivity to divalproex sodium, sodium valproate, or valproic acid.
Patients with known urea cycle disorders.
Women who are pregnant or of childbearing potential not using effective contraception when indicated for migraine prophylaxis.
Patients who have experienced multiorgan hypersensitivity reactions or serious dermatologic reactions to valproate.
Use for migraine prophylaxis in pregnant women due to fetal risk.
Patients with severe hypersensitivity reactions to any component of the formulation.

Drug Interactions

Enzyme-inducing antiepileptic drugs (e.g., phenytoin, carbamazepine, phenobarbital, primidone, rifampin) increase valproate clearance, decreasing plasma concentrations.
Enzyme inhibitors such as felbamate increase valproate plasma concentrations, necessitating dosage adjustments.
Aspirin reduces protein binding and inhibits valproate metabolism, increasing free valproate fraction significantly.
Carbapenem antibiotics (e.g., ertapenem, imipenem, meropenem) markedly reduce serum valproate levels, risking loss of seizure control.
Estrogen-containing hormonal contraceptives increase valproate clearance, potentially lowering valproate levels and efficacy.
Methotrexate reduces valproate concentrations; monitor therapy and adjust doses accordingly.
Valproate inhibits metabolism or displaces protein binding of diazepam, ethosuximide, lamotrigine, phenytoin, clonazepam, phenobarbital, and other AEDs, increasing their plasma levels and toxicity risk.
Co-administration with topiramate is associated with increased risk of hyperammonemia and encephalopathy.
Cannabidiol increases risk of elevated liver enzymes with valproate co-administration; monitor liver function tests closely.
Valproate decreases clearance of rufinamide leading to increased rufinamide levels; dose adjustments recommended.
Amitriptyline/nortriptyline plasma concentrations are increased; consider dosage adjustments.
Valproate increases free fraction of warfarin and other anticoagulants; coagulation parameters should be monitored.
Propofol levels increased when co-administered; reduce dose and monitor sedation.
Tolbutamide free fraction increased; clinical significance unknown but warrants monitoring.
Potential pharmacodynamic interaction with lithium and clozapine; monitor accordingly.

Preparations Of The Drug

Divalproex sodium extended-release tablets 250 mg: Pink, oval, biconvex, film-coated tablets with imprint 'U 380' designed for once-daily oral administration.
Divalproex sodium extended-release tablets 500 mg: Yellow, oval, biconvex, film-coated tablets with imprint 'U 381' designed for once-daily oral administration.
Inactive ingredients include colloidal silicon dioxide, ethylcellulose, hypromellose, lactose monohydrate, propyl gallate, stearic acid, talc, ferric oxide red (250 mg) or ferric oxide yellow (500 mg), titanium dioxide, triacetin, propylene glycol, and shellac glaze in the imprinting ink.
Tablets meet USP dissolution standards for extended-release formulations.
Packaged in bottles of 100 and 500 tablets with controlled room temperature storage recommendations (20° to 25°C).
Formulated to release active drug over an extended period providing more stable plasma levels and improved compliance versus multiple daily dosing.
Pharmaceutical quality controlled to ensure consistent drug release and bioavailability.
Available under various trademarks including Depakote, Depakote ER, and Depakote Sprinkles for multiple indications.
Manufactured by Unichem Laboratories Ltd., India, and distributed by Unichem Pharmaceuticals (USA), Inc.
Additional dosage forms such as delayed release tablets and sprinkle capsules exist but are separate from the extended-release tablets discussed.